Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences Inc (NQ: ALPN )

7.200 +0.030 (+0.42%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 136,588
Open 7.350
Bid (Size) 6.450 (1)
Ask (Size) 7.610 (1)
Prev. Close 7.170
Today's Range 7.098 - 7.380
52wk Range 6.000 - 14.40
Shares Outstanding 23,914,879
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
US Stock Futures Edge Higher; All Eyes On Fed Decision
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade on Wednesday after recording losses on Tuesday. The Dow Jones closed lower by more than 300 points, while the Nasdaq... 
Via Benzinga
General Mills, Lennar And 3 Stocks To Watch Heading Into Wednesday
With US stock futures trading slightly lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga

Performance

YTD
-48.16%
-48.16%
1 Month
-4.13%
-4.13%
3 Month
-16.38%
-16.38%
6 Month
-19.73%
-19.73%
1 Year
-33.21%
-33.21%

More News

Read More
Alpine Immune Sciences Announces Pricing of $100 Million Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Proposed Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
At R&D Day, Alpine Immune Highlights Updates On Autoimmune, Immuno-Oncology Programs
Via Benzinga
Alpine Immune Sciences to Highlight Clinical Updates on Autoimmune and Immuno-Oncology Programs at Inaugural R&D Day
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in September Investor Conferences
From Alpine Immune Sciences Inc.
Via Business Wire
Alpine Immune Sciences's Return On Capital Employed Overview
Via Benzinga
Alpine Immune Sciences Announces R&D Day to Provide Clinical Updates on Wholly-Owned Programs ALPN-303 and Davoceticept
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Inducement Grant to Andrew S. Sandler, M.D. Under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences: Q2 Earnings Insights
Via Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Via Benzinga
Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate
Via Benzinga
Just – Evotec Biologics and Alpine Immune Sciences Expand Partnership for Commercial Process Development of ALPN-303
From Alpine Immune Sciences Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Appoints Jörn Drappa, MD, PhD, to Board of Directors
From Alpine Immune Sciences Inc.
Via Business Wire
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022
From Alpine Immune Sciences Inc.
Via Business Wire
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Via Benzinga
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
From Alpine Immune Sciences, Inc.
Via Business Wire
FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer
Via Benzinga
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in May Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.